ArticleBMJ open2019

Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.

Nadine L de Boer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.